Nanoparticle-Enabled Immune-Dose Shaping in Breast Cancer Radiotherapy: Reconciling Tumor Immunogenicity with Systemic Immune Preservation
- 1Grigore T Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
- 22nd Department of Surgical Oncology, Regional Institute of Oncology, 700483 Iasi, Romania
Abstract
Radiotherapy can simultaneously promote tumor immunogenicity and damage the systemic immune compartments required to sustain antitumor responses. In breast cancer, radiation-induced lymphopenia is influenced by treatment geometry, irradiated volume, low-dose exposure, marrow and lymphoid irradiation, fractionation, and delivery characteristics, while nanoparticle radioenhancement can amplify tumor response through physical, redox, DNA-repair, and immune mechanisms. This hypothesis-driven translational review examines whether nanoparticle-generated biological amplification could be redirected from tumor intensification toward immune-dose shaping while preserving tumor control and immunogenicity. The evidence supports seven interacting dimensions of potential exchange: physical dose, volume/spatial exposure, distributed low-dose exposure, marrow dose, geometry/modality, fractionation, and temporal/delivery exposure. Formal nanoparticle-enabled dose exchange remains limited, with the clearest breast-specific evidence confined to in vitro isoeffect analysis; no study has yet demonstrated preserved tumor isoeffect and immunogenicity together with reduced multicompartment immune injury after nanoparticle-enabled exposure reduction. We, therefore, propose a dual-endpoint framework integrating tumor control, immunogenicity, multicompartment immune preservation, dosimetry, and nanoparticle biodistribution, together with a staged translational pathway from quantitative preclinical exchange studies to comparative clinical testing. This strategy remains hypothesis-generating, with triple-negative breast cancer representing a particularly informative initial setting.
Related
- A Drug-Specific, Half-Life-Adjusted Framework for Classifying CNS-Active Systemic Therapy Exposure During and After Radiotherapy
- Self-reported practice patterns for cognitive preservation during whole-brain radiotherapy: a multinational cross-sectional survey of radiation oncologists in the Middle East and North Africa
- Intranasal gold nanoparticle-antigen induces mucosal and systemic immunity against β-coronaviruses.
- The Predictive Value of the Systemic Immune‐Inflammation Index Combined With Clinical Stage for the Prognosis of Oesophageal Cancer Patients Treated With Radiotherapy: A Retrospective Cohort Study and Meta‐Analysis
- Reconciling motherhood ideology: a classic grounded theory of breastfeeding grief
BibTeX
@article{lunca2026nanoparticleenabled,
title = {{Nanoparticle-Enabled Immune-Dose Shaping in Breast Cancer Radiotherapy: Reconciling Tumor Immunogenicity with Systemic Immune Preservation}},
author = {Sorinel Lunca and Stefan Morarasu and Gabriel Mihail Dimofte},
journal = {International journal of molecular sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27198928},
url = {https://europepmc.org/article/PMC/PMC13666163},
note = {CC BY},
}
RIS
TY - JOUR
TI - Nanoparticle-Enabled Immune-Dose Shaping in Breast Cancer Radiotherapy: Reconciling Tumor Immunogenicity with Systemic Immune Preservation
AU - Sorinel Lunca
AU - Stefan Morarasu
AU - Gabriel Mihail Dimofte
PY - 2026
DA - 2026/10/01
JO - International journal of molecular sciences
DO - 10.3390/ijms27198928
UR - https://europepmc.org/article/PMC/PMC13666163
AB - Radiotherapy can simultaneously promote tumor immunogenicity and damage the systemic immune compartments required to sustain antitumor responses. In breast cancer, radiation-induced lymphopenia is influenced by treatment geometry, irradiated volume, low-dose exposure, marrow and lymphoid irradiation, fractionation, and delivery characteristics, while nanoparticle radioenhancement can amplify tumor response through physical, redox, DNA-repair, and immune mechanisms. This hypothesis-driven translational review examines whether nanoparticle-generated biological amplification could be redirected from tumor intensification toward immune-dose shaping while preserving tumor control and immunogenicity. The evidence supports seven interacting dimensions of potential exchange: physical dose, volume/spatial exposure, distributed low-dose exposure, marrow dose, geometry/modality, fractionation, and temporal/delivery exposure. Formal nanoparticle-enabled dose exchange remains limited, with the clearest breast-specific evidence confined to in vitro isoeffect analysis; no study has yet demonstrated preserved tumor isoeffect and immunogenicity together with reduced multicompartment immune injury after nanoparticle-enabled exposure reduction. We, therefore, propose a dual-endpoint framework integrating tumor control, immunogenicity, multicompartment immune preservation, dosimetry, and nanoparticle biodistribution, together with a staged translational pathway from quantitative preclinical exchange studies to comparative clinical testing. This strategy remains hypothesis-generating, with triple-negative breast cancer representing a particularly informative initial setting.
SN - 1422-0067
ER -